[HTML][HTML] P2. 03-025 prevalence of EGFR T790M mutation in NSCLC patients after afatinib failure, and subsequent response to osimertinib
M Hochmair, S Schwab, O Burghuber, R Koger… - Journal of Thoracic …, 2017 - jto.org
Background In patients with EGFR-mutant non-small-cell lung cancer (NSCLC), progression
inevitably occurs after 9 to 14 months of treatment with EGFR tyrosine kinase inhibitors …
inevitably occurs after 9 to 14 months of treatment with EGFR tyrosine kinase inhibitors …
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung …
N Oda, K Hotta, K Ninomiya, D Minami… - Cancer Chemotherapy …, 2018 - Springer
Purpose The aim of this study was to evaluate the efficacy of epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration using afatinib in patients …
receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration using afatinib in patients …
Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb …
L Paz-Ares, EH Tan, L Zhang, V Hirsh… - Annals of …, 2016 - annalsofoncology.org
Background The irreversible ErbB family blocker, A, and the reversible EGFR TKI, G, are
approved for 1st-line treatment (tx) of advanced EGFRm+ NSCLC. In LL7, A (40 mg/d) …
approved for 1st-line treatment (tx) of advanced EGFRm+ NSCLC. In LL7, A (40 mg/d) …
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
MS Holleman, H van Tinteren, HJM Groen… - OncoTargets and …, 2019 - Taylor & Francis
Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …
[HTML][HTML] Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer …
HA Jung, MH Hong, HW Lee, KH Lee… - … lung cancer Research, 2022 - ncbi.nlm.nih.gov
Background Irrespective of the first-line epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor chosen, acquired resistance to therapy is inevitable. Therefore, a key …
kinase inhibitor chosen, acquired resistance to therapy is inevitable. Therefore, a key …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
First-or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
ACC Huang, CH Huang, JS Ju… - Therapeutic …, 2021 - journals.sagepub.com
Background: There are limited comparisons of first-and second-generation EGFR tyrosine
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
[HTML][HTML] Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor …
S Park, SY Lee, D Kim, YS Sim, JS Ryu, J Choi, SH Lee… - BMC cancer, 2021 - Springer
Background Epidermal growth factor receptor (EGFR) mutations in non–small-cell lung
cancer predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation types are …
cancer predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation types are …
P1. 34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC
SP Aix, K Park, EH Tan, K O'Byrne, L Zhang… - Journal of Thoracic …, 2016 - jto.org
Background The irreversible ErbB family blocker afatinib and the reversible EGFR TKI
gefitinib are approved for first-line treatment of advanced EGFRm+ NSCLC. This phase IIb …
gefitinib are approved for first-line treatment of advanced EGFRm+ NSCLC. This phase IIb …